5-Methoxy-5-oxopentanoate

• 分子结构分类: 有机化合物 - 脂质和类脂质分子 - 脂肪酰基
• 英文名称: 5-Methoxy-5-oxopentanoate
• 化学式: C6H9O4-
• 分子量: 145.13
• InChiKey: IBMRTYCHDPMBFN-UHFFFAOYSA-M

计算性质

• 辛醇/水分配系数(LogP)：
  0.9
• 重原子数：
  10
• 可旋转键数：
  4
• 环数：
  0.0
• sp3杂化的碳原子比例：
  0.67
• 拓扑面积：
  66.4
• 氢给体数：
  0
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  (+)-(3aS,4R,7aS)-4-hydroxy-4-(m-tolylethynyl)-octahydro-indole-1-carboxylic acid methyl ester 、 5-Methoxy-5-oxopentanoate 以to yield (3aR,4S,7aR)-1-(methoxycarbonyl)-4-(m-tolylethynyl)octahydro-1H-indol-4-yl methyl glutarate的产率得到(3aR,4S,7aR)-1-(methoxycarbonyl)-4-(m-tolylethynyl)octahydro-1H-indol-4-yl methyl glutarate
  参考文献：
  名称：

  4-Tolyl-ethynyl-octahydro-indole-1-ester derivatives

  摘要：

  该发明涉及化合物(I)的公式，其中取代基如规范中所定义；以自由形式或盐形式存在；其制备方法，其用作药物以及包含它们的药物。

  公开号：

  US20130303538A1

文献信息

• Derivatives of succinic and glutaric acids and analogs thereof useful as inhibitors of phex
  申请人：Gravel Denis

  公开号：US20060135480A1

  公开（公告）日：2006-06-22

  The present invention relates to derivatives of succinic and glutaric acids and analogues thereof, having the following general formula (I), useful as inhibitors of PHEX. These derivatives are useful for promoting generation of bone mass and treating or preventing diseases or conditions associated with a phosphate metabolism defect. Methods for preparation and intermediates are also disclosed.

  本发明涉及琥珀酸和戊二酸的衍生物及其类似物，具有以下一般式（I），可用作PHEX的抑制剂。这些衍生物有助于促进骨量的生成，并治疗或预防与磷酸盐代谢缺陷相关的疾病或病症。本发明还公开了制备方法和中间体。
• Carbamoyl-type benzofuran derivatives
  申请人：Kawaguchi Takayuki

  公开号：US20060247273A1

  公开（公告）日：2006-11-02

  The present invention provides a carbamoyl-type benzofuran derivative of the formula [1]: wherein Ring Z is a group of the formula: etc.; A is a single bond, and the like; Y is a cycloalkanediyl group, etc.; R 4 and R 5 are the same or different and each is an optionally substituted lower alkyl group, etc.; R 1 is a halogen atom, etc.; Ring B of the formula: is an optionally substituted benzene ring; and R 3 is a hydrogen atom. etc., or a pharmaceutically acceptable salt thereof, which is useful as an FXa inhibitor.

  本发明提供了一种公式[1]的氨基甲酰基苯并呋喃衍生物： 其中，环Z是公式等的一组；A是单键等；Y是环烷基二基等；R4和R5相同或不同，每个是可选取的低取代基等；R1是卤素原子等；环B是可选取的苯环；R3是氢原子等；或其药学上可接受的盐，作为FXa抑制剂具有用处。
• Thiazole Derivatives and Use Thereof
  申请人：Quattropani Anna

  公开号：US20080221180A1

  公开（公告）日：2008-09-11

  The present invention is related to thiazole derivatives of Formula (I) in particular for the treatment and/or prophylaxis of autoimmune disorders and/or inflammatory diseases, cardiovascular diseases, neurodegenerative diseases, bacterial or viral infections, kidney diseases, platelet aggregation, cancer, transplantation, graft rejection or lung injuries.

  本发明涉及式（I）的噻唑衍生物，特别是用于治疗和/或预防自身免疫性疾病和/或炎症性疾病、心血管疾病、神经退行性疾病、细菌或病毒感染、肾脏疾病、血小板聚集、癌症、移植、移植排斥或肺损伤。
• Derivatives of succinic and glutaric acids and analogs thereof useful as inhibitors of PHEX
  申请人：Gravel Denis

  公开号：US20060287280A1

  公开（公告）日：2006-12-21

  The present invention relates to derivatives of succinic and glutaric acids and analogues thereof, having the following general formula: useful as inhibitors of PHEX. These derivatives are useful for promoting generation of bone mass and treating or preventing diseases or conditions associated with a phosphate metabolism defect. Methods for preparation and intermediates are also disclosed.

  本发明涉及琥珀酸和戊二酸及其类似物的衍生物，其具有以下一般式：用作PHEX的抑制剂。这些衍生物有助于促进骨量的生成，并用于治疗或预防与磷酸盐代谢缺陷有关的疾病或病况。本发明还公开了制备方法和中间体。
• Combretastatin analogs with tubulin binding activity
  申请人：Pinney G. Kevin

  公开号：US20060293394A1

  公开（公告）日：2006-12-28

  Analogs of combretastatin have been discovered which demonstrate impressive cytotoxicity as well as a remarkable ability to inhibit tubulin polymerization. Such compounds are excellent clinical candidates for the treatment of cancer in humans. In addition, certain of these ligands, as pro-drugs, may well prove to be tumor selective vascular targeting chemotherapeutic agents or to have vascular targeting activity resulting in the selective prevention and/or destruction of nonmalignant proliferating vasculature.

  已经发现了类似于孟宗竹素的化合物，它们表现出令人印象深刻的细胞毒性以及抑制微管聚合的显著能力。这些化合物是治疗人类癌症的优秀临床候选药物。此外，其中某些配体作为前药，可能证明是肿瘤选择性靶向血管化学治疗药物，或具有靶向血管活性，从而选择性地预防和/或破坏非恶性增殖血管。